Ask most people what stands between a patient and a diagnostic result and they'll point at the lab. The lab matters enormously. But it is rarely where the system breaks.
The system breaks in the gaps: the kit that arrived without clear instructions, the sample that sat too long in transit, the result that couldn't be matched back to the right patient, the reminder that never went out. Each gap looks small. Together they decide whether a screening program reaches people or misses them.
The United States has a demand problem and a capacity problem at the same time. The at-home testing market is growing fast — US home diagnostics is projected to roughly double from about $4.2 billion in 2024 to $7.5 billion by 2034, and self-collection is the fastest part of it.[1] Meanwhile the laboratory workforce that has to absorb all those samples is stretched thin, short by tens of thousands of professionals.[2] More tests, fewer hands to run them.
You can't hire your way out of a plumbing problem
When demand rises faster than staff, the instinct is to recruit. But you cannot quickly manufacture experienced medical laboratory scientists — training programs have shrunk, not grown.[2] The faster lever is infrastructure: automate the kit build, digitize the chain of custody, and remove the manual reconciliation that eats a lab's most scarce hours.
Treating the kit, the logistics and the data as one connected layer isn't a nicety. It's how you add capacity without adding headcount.
That is the whole thesis behind RDi USA. We don't run the assay — that's the lab's job, and we're not interested in competing with our customers. We run the layer underneath: 130+ regulated kit configurations built on automated, camera-verified lines, moved compliantly, and connected end to end by +CURA so that every sample is accounted for from collection to result to EHR.
Infrastructure is boring until it isn't
Nobody gets excited about plumbing — until the taps run dry. Diagnostic infrastructure is the same. It is invisible when it works and catastrophic when it doesn't. America's screening ambitions, its decentralized trials, its payer quality programs all quietly depend on it.
So my argument is simple. Stop buying kits, logistics and software as three separate things from three separate places and hoping they meet in the middle. Buy the layer. That's the problem worth solving, and it's the one we've built the company around.